BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.02 (-0.19%)

Stability Price

Overvalued by 98.20%

Company Metrics

  • 0 P/E
  • 39.71 P/S
  • 8.91 P/B
  • -0.613 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0.00 / N/A % Dividend
  • 1.21M Avg. Vol.
  • 742.3M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Reaction to Confirmed Ebola Case in U.S. — UPDATED
24/7 Wall St. - Sep 30, 2014
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was up 5% at $9.78 in the after-hours, but that was after a 6.7% drop to $9.78 in regular trading.
Biocryst Pharmaceuticals Inc. (BCRX) Is Rising After U.S. Ebola Case Confirmed - RTT News
Morning Buzz: Tekmira Pharmaceuticals (TKMR), Biocryst Pharmaceuticals ... - Wall Street Pit
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'
Forbes - Aug 29, 2014
BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
Hope For Ebola Cure - Bidness ETC
BioCryst expects to begin Ebola study in weeks - Yahoo News
Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)
TheStreet.com - Oct 15, 2014
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Biocryst Pharmaceuticals ...
Why BioCryst Pharmaceuticals Inc. Shares Soared
Motley Fool - May 27, 2014
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Pharmaceuticals (BCRX) Hereditary Angioedema Trial Positive Results ... - SmallCap Network
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
Wall Street Pit - Aug 8, 2014
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
Notable Analyst Actions: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ... - Financial Wired
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
ETF Daily News - Aug 5, 2014
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal Stock - TheStreet.com
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ... - Seeking Alpha (registration)
Why BioCryst Pharmaceuticals, Inc. Shares Spiked Higher
Motley Fool - Feb 25, 2014
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biopharmaceutical company that develops drugs to block enzymes involved in the development of various diseases, jumped as much as 15% after announcing that its new drug application for ...
BioCryst Pharmaceuticals, Inc. (BCRX) news: BioCyst Pharma +12% after FDA ... - Seeking Alpha
BioCryst Announces Peramivir NDA Acceptance by the FDA - GlobeNewswire (press release)
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
TheStreet.com - Sep 24, 2014
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
BioCryst And NewLink Surge On Latest US Ebola Case
Bidness ETC - Oct 16, 2014
BioCryst Pharmaceuticals, Inc. (BCRX) surged 14.7% yesterday following news that a nurse, who had been in direct physical contact with Thomas Duncan, had also contracted Ebola.
Small Cap Biotech Game Changers: NewLink Genetics Corp (NASDAQ:NLNK ... - StreetWise Report
BioCryst Pharmaceuticals, Inc. - Special Call
Seeking Alpha - Jul 22, 2013
Good day, ladies and gentlemen, and welcome to the BioCryst BCX4161 Phase I Results and HAE Update Conference Call. [Operator Instructions] As a reminder, today's conference call is being recorded.